Selected research
Market Structure
Global Plasma Derived Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Plasma Derived Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Plasma Derived Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Plasma Derived Medicine include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Plasma Derived Medicine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Plasma Derived Medicine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Plasma Derived Medicine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Plasma Derived Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.
Plasma Derived Medicine Segment by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Plasma Derived Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma Derived Medicine industry.
Chapter 3: Detailed analysis of Plasma Derived Medicine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Plasma Derived Medicinerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Albumin
- Immune Globulin
- Coagulation Factor
- Others
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Yuanda Shuyang
- Takeda
- Weiguang Bio
- Tiantan Bio
- CBPO
- Shuanglin Bio
- RAAS
- Nanyue Bio
- Hualan Bio
- Boya Bio
- Octapharma
- LFB Group
- KM Biologics
- Kedrion
- Grifols
- CSL
- BPL
- Biotest
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Plasma Derived Medicine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Albumin
- 1.2.3 Immune Globulin
- 1.2.4 Coagulation Factor
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Plasma Derived Medicine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Retail Pharmacy
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Plasma Derived Medicine Growth Trends by Region
- 1.5.1 Global Plasma Derived Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Plasma Derived Medicine Market Size by Region (2021-2026)
- 1.5.3 Plasma Derived Medicine Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Plasma Derived Medicine Market Dynamics
- 2.1 Plasma Derived Medicine Industry Trends
- 2.2 Plasma Derived Medicine Industry Drivers
- 2.3 Plasma Derived Medicine Industry Opportunities and Challenges
- 2.4 Plasma Derived Medicine Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Plasma Derived Medicine Revenue by Company (2021-2026)
- 3.2 Global Plasma Derived Medicine Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Plasma Derived Medicine Key Company Head office and Area Served
- 3.4 Global Plasma Derived Medicine Company, Product Type & Application
- 3.5 Global Plasma Derived Medicine Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Plasma Derived Medicine Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Plasma Derived Medicine Players Market Share by Revenue in 2025
- 3.6.3 2025 Plasma Derived Medicine Tier 1, Tier 2, and Tier 3
4 Plasma Derived Medicine Market by Type
- 4.1 Global Plasma Derived Medicine Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Plasma Derived Medicine Market Size by Type (2021-2032)
- 4.3 Global Plasma Derived Medicine Market Size Share by Type (2021-2032)
5 Plasma Derived Medicine Market by Application
- 5.1 Global Plasma Derived Medicine Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Plasma Derived Medicine Market Size by Application (2021-2032)
- 5.3 Global Plasma Derived Medicine Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Yuanda Shuyang
- 6.1.1 Yuanda Shuyang Company Information
- 6.1.2 Yuanda Shuyang Business Overview
- 6.1.3 Yuanda Shuyang Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
- 6.1.5 Yuanda Shuyang Recent Developments
- 6.2 Takeda
- 6.2.1 Takeda Company Information
- 6.2.2 Takeda Business Overview
- 6.2.3 Takeda Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Takeda Plasma Derived Medicine Product Portfolio
- 6.2.5 Takeda Recent Developments
- 6.3 Weiguang Bio
- 6.3.1 Weiguang Bio Company Information
- 6.3.2 Weiguang Bio Business Overview
- 6.3.3 Weiguang Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
- 6.3.5 Weiguang Bio Recent Developments
- 6.4 Tiantan Bio
- 6.4.1 Tiantan Bio Company Information
- 6.4.2 Tiantan Bio Business Overview
- 6.4.3 Tiantan Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
- 6.4.5 Tiantan Bio Recent Developments
- 6.5 CBPO
- 6.5.1 CBPO Company Information
- 6.5.2 CBPO Business Overview
- 6.5.3 CBPO Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 CBPO Plasma Derived Medicine Product Portfolio
- 6.5.5 CBPO Recent Developments
- 6.6 Shuanglin Bio
- 6.6.1 Shuanglin Bio Company Information
- 6.6.2 Shuanglin Bio Business Overview
- 6.6.3 Shuanglin Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
- 6.6.5 Shuanglin Bio Recent Developments
- 6.7 RAAS
- 6.7.1 RAAS Company Information
- 6.7.2 RAAS Business Overview
- 6.7.3 RAAS Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 RAAS Plasma Derived Medicine Product Portfolio
- 6.7.5 RAAS Recent Developments
- 6.8 Nanyue Bio
- 6.8.1 Nanyue Bio Company Information
- 6.8.2 Nanyue Bio Business Overview
- 6.8.3 Nanyue Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
- 6.8.5 Nanyue Bio Recent Developments
- 6.9 Hualan Bio
- 6.9.1 Hualan Bio Company Information
- 6.9.2 Hualan Bio Business Overview
- 6.9.3 Hualan Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
- 6.9.5 Hualan Bio Recent Developments
- 6.10 Boya Bio
- 6.10.1 Boya Bio Company Information
- 6.10.2 Boya Bio Business Overview
- 6.10.3 Boya Bio Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
- 6.10.5 Boya Bio Recent Developments
- 6.11 Octapharma
- 6.11.1 Octapharma Company Information
- 6.11.2 Octapharma Business Overview
- 6.11.3 Octapharma Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Octapharma Plasma Derived Medicine Product Portfolio
- 6.11.5 Octapharma Recent Developments
- 6.12 LFB Group
- 6.12.1 LFB Group Company Information
- 6.12.2 LFB Group Business Overview
- 6.12.3 LFB Group Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 LFB Group Plasma Derived Medicine Product Portfolio
- 6.12.5 LFB Group Recent Developments
- 6.13 KM Biologics
- 6.13.1 KM Biologics Company Information
- 6.13.2 KM Biologics Business Overview
- 6.13.3 KM Biologics Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
- 6.13.5 KM Biologics Recent Developments
- 6.14 Kedrion
- 6.14.1 Kedrion Company Information
- 6.14.2 Kedrion Business Overview
- 6.14.3 Kedrion Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Kedrion Plasma Derived Medicine Product Portfolio
- 6.14.5 Kedrion Recent Developments
- 6.15 Grifols
- 6.15.1 Grifols Company Information
- 6.15.2 Grifols Business Overview
- 6.15.3 Grifols Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Grifols Plasma Derived Medicine Product Portfolio
- 6.15.5 Grifols Recent Developments
- 6.16 CSL
- 6.16.1 CSL Company Information
- 6.16.2 CSL Business Overview
- 6.16.3 CSL Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 CSL Plasma Derived Medicine Product Portfolio
- 6.16.5 CSL Recent Developments
- 6.17 BPL
- 6.17.1 BPL Company Information
- 6.17.2 BPL Business Overview
- 6.17.3 BPL Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 BPL Plasma Derived Medicine Product Portfolio
- 6.17.5 BPL Recent Developments
- 6.18 Biotest
- 6.18.1 Biotest Company Information
- 6.18.2 Biotest Business Overview
- 6.18.3 Biotest Plasma Derived Medicine Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Biotest Plasma Derived Medicine Product Portfolio
- 6.18.5 Biotest Recent Developments
7 North America
- 7.1 North America Plasma Derived Medicine Market Size (2021-2032)
- 7.2 North America Plasma Derived Medicine Market Size by Type
- 7.2.1 North America Plasma Derived Medicine Market Size by Type (2021-2026)
- 7.2.2 North America Plasma Derived Medicine Market Size by Type (2027-2032)
- 7.2.3 North America Plasma Derived Medicine Market Share by Type (2021-2032)
- 7.3 North America Plasma Derived Medicine Market Size by Application
- 7.3.1 North America Plasma Derived Medicine Market Size by Application (2021-2026)
- 7.3.2 North America Plasma Derived Medicine Market Size by Application (2027-2032)
- 7.3.3 North America Plasma Derived Medicine Market Share by Application (2021-2032)
- 7.4 North America Plasma Derived Medicine Market Size by Country
- 7.4.1 North America Plasma Derived Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Plasma Derived Medicine Market Size by Country (2021-2026)
- 7.4.3 North America Plasma Derived Medicine Market Size by Country (2027-2032)
- 7.4.4 North America Plasma Derived Medicine Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Plasma Derived Medicine Market Size (2021-2032)
- 8.2 Europe Plasma Derived Medicine Market Size by Type
- 8.2.1 Europe Plasma Derived Medicine Market Size by Type (2021-2026)
- 8.2.2 Europe Plasma Derived Medicine Market Size by Type (2027-2032)
- 8.2.3 Europe Plasma Derived Medicine Market Share by Type (2021-2032)
- 8.3 Europe Plasma Derived Medicine Market Size by Application
- 8.3.1 Europe Plasma Derived Medicine Market Size by Application (2021-2026)
- 8.3.2 Europe Plasma Derived Medicine Market Size by Application (2027-2032)
- 8.3.3 Europe Plasma Derived Medicine Market Share by Application (2021-2032)
- 8.4 Europe Plasma Derived Medicine Market Size by Country
- 8.4.1 Europe Plasma Derived Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Plasma Derived Medicine Market Size by Country (2021-2026)
- 8.4.3 Europe Plasma Derived Medicine Market Size by Country (2027-2032)
- 8.4.4 Europe Plasma Derived Medicine Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Plasma Derived Medicine Market Size (2021-2032)
- 9.2 China Plasma Derived Medicine Market Size by Type
- 9.2.1 China Plasma Derived Medicine Market Size by Type (2021-2026)
- 9.2.2 China Plasma Derived Medicine Market Size by Type (2027-2032)
- 9.2.3 China Plasma Derived Medicine Market Share by Type (2021-2032)
- 9.3 China Plasma Derived Medicine Market Size by Application
- 9.3.1 China Plasma Derived Medicine Market Size by Application (2021-2026)
- 9.3.2 China Plasma Derived Medicine Market Size by Application (2027-2032)
- 9.3.3 China Plasma Derived Medicine Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Plasma Derived Medicine Market Size (2021-2032)
- 10.2 Asia Plasma Derived Medicine Market Size by Type
- 10.2.1 Asia Plasma Derived Medicine Market Size by Type (2021-2026)
- 10.2.2 Asia Plasma Derived Medicine Market Size by Type (2027-2032)
- 10.2.3 Asia Plasma Derived Medicine Market Share by Type (2021-2032)
- 10.3 Asia Plasma Derived Medicine Market Size by Application
- 10.3.1 Asia Plasma Derived Medicine Market Size by Application (2021-2026)
- 10.3.2 Asia Plasma Derived Medicine Market Size by Application (2027-2032)
- 10.3.3 Asia Plasma Derived Medicine Market Share by Application (2021-2032)
- 10.4 Asia Plasma Derived Medicine Market Size by Country
- 10.4.1 Asia Plasma Derived Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Plasma Derived Medicine Market Size by Country (2021-2026)
- 10.4.3 Asia Plasma Derived Medicine Market Size by Country (2027-2032)
- 10.4.4 Asia Plasma Derived Medicine Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Plasma Derived Medicine Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Plasma Derived Medicine Market Size by Type
- 11.2.1 South America, Middle East & Africa Plasma Derived Medicine Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Plasma Derived Medicine Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Plasma Derived Medicine Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Plasma Derived Medicine Market Size by Application
- 11.3.1 South America, Middle East & Africa Plasma Derived Medicine Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Plasma Derived Medicine Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Plasma Derived Medicine Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Plasma Derived Medicine Market Size by Country
- 11.4.1 South America, Middle East & Africa Plasma Derived Medicine Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Plasma Derived Medicine Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Plasma Derived Medicine Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Plasma Derived Medicine Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst